↩ Go Back
Need help?

Generic Pharmaceutical Business Investment Opportunities

Showing 1 - 15 of 45 Generic Pharmaceutical Business Investment Opportunities. Invest in a Generic Pharmaceutical Business.

Filters
  • Generic Pharmaceuticals

  • Investment Opportunities

 

Newly Established Generic Pharmaceuticals Company Investment Opportunity in Baddi, India

Pharmaceuticals company planning to offer a wide range of tablets with a strong revenue outlook.
1. The business operates in the generic pharmaceuticals industry, offering a wide range of tablets except narcotics-related products. 2. Located in Baddi, the company adheres to Good Manufacturing Practice (GMP) and World Health Organization (WHO) Drugs and Cosmetics guidelines for its machinery and facilities. 3. The business boasts Microbiological and Chemical laboratories compliant with the latest guidelines, ensuring quality control and regulatory compliance. 5. The owner, who has prior experience in manufacturing and runs a successful marketing company, possesses valuable connections within the pharmaceutical industry. 6. With plans to operate at 50% capacity in the next 6 months, the business projects sales of over INR 50 crores, with an expected net profit of INR 8 crores, reflecting a strong revenue and profitability outlook. 7. The business benefits from the owner's industry expertise and established relationships with pharmaceutical clients, which may contribute to its growth and success. 8. The focus on generic pharmaceuticals and compliance with industry standards positions the business to capitalize on the growing demand for affordable and accessible medication. 9. The company was incorporated in 2019 but was not able to start operations due to the covid crisis, the promoters are looking to start the business now and are also work on the lab to ensure that the required licenses are in place.
Pharmaceuticals company planning to offer a wide range of tablets with a strong revenue outlook.
7   Baddi
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 240 K for 25%
Contact Business

Newly Established Generic Pharmaceuticals Company Investment Opportunity in Nashik, India

Pharma manufacturing company focusing on small volume parenterals, seeking investment for plant completion and operations.
- Pharma manufacturing company, located in Nashik. - The plant is in its final stage of commissioning and will focus on the production of small volume parenterals in ampules, vials, PFS, and lyophilized products. - Technical inspection is pending, post which the business can obtain drug manufacturing license to start the manufacturing process. - Will be manufactured on a principle-to-principle and loan license basis for both local and export markets. - The product line includes human injectable products falling under drug categories such as antibiotics, steroids, analgesics etc. - Business model involves manufacturing products under the brand and formulation of other major pharmaceutical companies and supplying them for marketing and distribution. - The business is registered with the Ministry of Corporate Affairs (MCA), holds a Permanent Account Number (PAN), and is registered with the Micro, Small, and Medium Enterprises (MSME).
7.1   Nashik
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 240 K for 10%
Contact Business

Newly Established Generic Pharmaceuticals Company Investment Opportunity in Dhaka, Bangladesh

Pharma manufacturing business with 52 years of history and 43 patents, seeking investment for revival.
- Pharmaceutical business located in Dhaka, Bangladesh, has a rich history of 52 years in the industry, having recently been acquired by new management. - The brand, licenses, registrations, client base, and property have been transferred to the new owners. - Was supplying across Bangladesh, the Middle East, and African countries under its own branding. - The business was temporarily closed down three years ago due to personal reasons, but it is now in the process of re-establishing existing contracts and resuming production. - With 43 patents from medical authorities and various licenses including drug manufacturing, IRC, and Export & Import, the company has a strong foundation for pharmaceutical production and distribution. - The pharmaceutical company manufactured a diverse range of drug formulations, including liquid, capsule, tablet, suspension, syrup, injection, aerosol spray & inhaler, injections, bolus, premix powder, premix solutions, and bulk drugs. - Manufactured drug categories include - antibiotics, antibacterials, chemotherapeutics, antiprotozoals, antidiarrhoeal, antidiabetic, antihistamines, NSAIDs, antihypertensives, multivitamins etc. - The company possesses a broad client base, serving wholesalers, pharmacies, hospitals, clinics, and distributors, indicating its reach and potential for growth in both domestic and international markets. - Revenue will be primarily generated through the sale of generic medications, with a focus on cost-effective production and competitive pricing strategies, positioning the business well for market success. - The company is led by experienced professionals with a background in pharmaceutical manufacturing, research, and business management, indicating strong leadership and expertise within the organization. - Had established strong relationships with suppliers of raw materials, regulatory authorities, distribution partners, and healthcare institutions. Have started re-establishing existing contracts and will restart the supply. Will continue to manufacture under the existing brand. - Additionally, the current owners are into manufacturing and supplying medical equipment to hospitals and healthcare facilities, thereby providing an opportunity to establish new contracts.
6.1   Dhaka
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 36 Mn for 50%
Contact Business

Newly Established Generic Pharmaceuticals Business Investment Opportunity in Gangasagar, India

Seeking investment to start a pharmaceutical drug manufacturing business in West Bengal.
- Business owner of a drug wholesale business planning to establish a pharmaceutical drug manufacturing plant. - The focus will be on creating a portfolio of drugs under the company's own brand name. - Initially, the manufacturing will concentrate on oral tablets and capsules, with future plans for expansion into other drug categories. - The company aims to supply its products to distributors across West Bengal, Jharkhand, Bihar, and Odisha. - Raw materials for the manufacturing process will be sourced from Ahmedabad and Visakhapatnam. - Will be obtaining drug license and FDA approval once the business launches.
5.6   Gangasagar
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 600 K for 50%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in Colombo, Sri Lanka

Company looking to manufacture and supply tablets to the government of Sri Lanka seeks investment.
- The project is to manufacture and supply tablets to the government of Sri Lanka up to 860mln per annum on a buyback guarantee and cost plus 20% margin. - The company can sell also in the private market which has a 40% profit margin. - Own 9.25-acre land valued at USD 1mln approx. - The license is issued and a government buyback agreement is signed. - The project is in plug and play stage where the investor can mobilize immediately. - Commercial manufacturing can commence in 8 months.
7.2   Colombo
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 15 Mn for 75%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in New York, United States

Generic complex injectable pharmaceutical manufacturer with 5 drugs pending approval and proven track record.
- The two main partners sold their stake in a previous company almost 10 years back and have now created their own new company. - They hold over 40 patents and are on the verge of their first approved generic complex injectable drug in a couple of months. - The facility was inspected very recently by the FDA and passed. - We have 5 drugs pending approval with a total market value of over USD 4B and only a few competitors. - The company should be worth USD 2B in another 3 years. - The business has not generated any revenue because we have been in the process of R&D in developing these drugs for the past 6 years and have invested over USD 40 million in the business.
Generic complex injectable pharmaceutical manufacturer with 5 drugs pending approval and proven track record.
7.4   New York
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 20 Mn for 5%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in Indore, India

Manufacturer of APIs and API intermediates for various therapeutic areas in domestic and international markets.
- API manufacturing company based in Indore, India. For the past 3 decades, this company has focused on API development, manufacturing, and marketing of APIs and intermediates. It has a state-of-the-art manufacturing facility and is a state GMP-certified plant facility. - This is a research-driven organization – that develops technology, translates it to production, and then delivers it to customers. With a strong commitment to excellence in product quality (which is never compromised) and adherence to strict delivery schedules, they are presently exporting to 14 countries around the world. - The company’s strength lies in providing extended support to its customers. Their success has been validated by what they hold the dearest – product excellence and customer service. The company believes that long-term business is rooted in values and business ethics. - It is one of the leading manufacturers of Tinidazole and Ornidazole, which are considered anti-protozoal molecules, a segment of bulk drugs. Sales have shown an increasing trend. - The company has received Good Manufacturing Practices (GMP) Certificate from the Office of the Controller of Food and Drugs Administration, Madhya Pradesh. Note: this transaction is being handled by an advisory firm based in Rajkot.
6.5   Indore
Run Rate Sales
USD 4.6 million
EBITDA Margin
12 %
Financial Investment
USD 12 Mn for 25%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in Davie, United States

OTC and generic pharmaceutical manufacturer located in South Florida with 6 OTC products.
Currently have 6 OTC topical products in the product portfolio, with an expected 1 additional OTC cream to launch by this year. Product sales are currently generated through Amazon and Walmart listings. We have been growing at 8-10 percent annually.
OTC and generic pharmaceutical manufacturer located in South Florida with 6 OTC products.
7.7   Davie
Run Rate Sales
USD 504 thousand
EBITDA Margin
40 %
Financial Investment
USD 250 K for 10%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in Tirana, Albania

Company manufacturing and marketing of pharmaceutical products for health care seeks investment.
- Our research and development department reflects our full commitment to delivering to society. - The revolutionary pharmaceuticals, acquired through groundbreaking ideas and high-standard research and development by each individual employee challenge innovation, so as to help enable patients and their families to lead healthier and more fulfilling lives. It also expresses our corporate mission symbolically, cooperating with a wide range of companies worldwide. - With a wide variety of drugs and a tradition in manufacturing for needs, we have cooperated with companies from Spain, Italy, and Turkey, looking forward to offering a wide range of healthcare products, also for well-being, with pre-ordered dosage forms for your efficiency and gut health. - The promoter is an investor representing the company who is based out of Istanbul.
8.1   Tirana
Run Rate Sales
USD 250 thousand
EBITDA Margin
17 %
Financial Investment
USD 800 K for 49%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in Muscat, Oman

Pharmaceutical manufacturer supplying superior quality dietary supplements/OTC products to MENA region.
- We are an Oman-based company, with offices in the UK and India, manufacturing our own products in a GMP-certified European facility. - The formulations are done by us and the production is outsourced. - Currently, 7 SKUs/products have been launched in Oman. - We are ready to launch the products in other GCC countries and need funds to start operations in the GCC region immediately. - Our products had an excellent response in Oman. - Our sister concern is the distributor for Oman, and we have appointed one distributor for each GCC country. - The full company name and other details are to be shared upon connecting and assessing the investor. - Promoters have 13 years of experience in the field.
8.6   Muscat
Run Rate Sales
USD 110 thousand
EBITDA Margin
30 - 40 %
Financial Investment
USD 1.3 Mn for 25%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in Barcelona, Spain

Barcelona based pharmaceutical company seeks investment to expand to other counties.
- Well established pharmaceutical company that has been operational for over 22 years. - Company manufactures and sells generic medicines under our own brand name. - Company has 3 directors and has no liability. - Business has its own manufacturing facility and has also partnered with other manufacturers to produce medicines. - Medicines are sold to doctors, pharma chains and distributors.
8.9   Barcelona
Run Rate Sales
USD 640 thousand
EBITDA Margin
22 %
Financial Investment
USD 530 K for 15%
Contact Business

Generic Pharmaceuticals Business Investment Opportunity in Maharashtra, India

Brand new factory for generic bulk drugs pharmaceutical manufacturing in Western India with regulatory approvals.
- Manufacturer of ready-to-fill pellets and directly compressible granules for tableting. - The unit is also engaged in developing new products like MUPS and modified release pellets. - The unit is set up in a 100,000 sq. ft. premises with all supporting facilities for manufacturing. - Company will be involved in the white labeling. - In talks with large domestic and international pharma companies and even Walmart. - Test run is done and they will soon commence production. - Family-owned general partnership with two owners having a 60:40 ownership pattern. - New entity with a bank loan of INR 21 crore. - The advisor handling this transaction is based in Mumbai, Maharashtra.
Brand new factory for generic bulk drugs pharmaceutical manufacturing in Western India with regulatory approvals.
7.5   Maharashtra
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 3.6 Mn for 25%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in New Delhi, India

Business planning on setting up capsule manufacturing plant seeking investment to set up the plant.
- We are a pharmaceutical trade (sales) business with 13 years of experience. - We plan on starting our own capsule manufacturing plant and seek investment for the same. - Have already acquired an industrial land on lease in Madhya Pradesh. - Business has connections in the pharmaceutical industry all over India. - The plant will be equipped with the latest machinery and equipment. - Have estimated a turnover of INR 15 crore in the 1st year based on the market conditions and the future manufacturing potential of the business. - There are 2 partners in the business with 75%-25% shareholding. - Business is debt-free.
6.6   New Delhi
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 700 K for 30%
Contact Business

Generic Pharmaceuticals Business Investment Opportunity in Gorakhpur, India

Medicine and health supplement manufacturing business seeking investment to cover more distribution area.
- We are a generic pharmaceutical business. - Manufacturing is done by a third party and the products are sold under our brand name. - Our representatives approach doctors to inform them about our products and get orders for them. - Business is managed by 2 people with an equal stake in it. - Business is debt-free.
5.4   Gorakhpur
Run Rate Sales
USD 100 thousand
EBITDA Margin
20 %
Financial Investment
USD 120 K for 10%
Contact Business

Generic Pharmaceuticals Company Investment Opportunity in Navi Mumbai, India

Seeking Investment: Pharma-marketing company looking to start a pharmaceutical manufacturing unit & brand name.
- Our business is essentially a pharmaceutical marketing company that sells a broad range of medicines from multiple brands to its clients. - We have about 60 clients who are essentially pharmaceutical companies and international distributors in the East African countries like Kenya, Burundi, Malawi, etc. These clients provide us with recurring purchase orders. - The entire revenue of the company is generated through the export of these medicines to our clients. There are no domestic clients. However, we will soon commence undertaking clients in India as well. - Currently, we are dealing in 39 different brand names such as Cipla, Glenmark, etc. The products are supplied on the basis of purchase orders received. Logistics support is outsourced. This line of operations contributing to 100 percent of the company's revenue. - We are now seeking to expand our operations and start our own pharmaceutical brand name & manufacturing unit. The majority of the proceeds from this investment will be used to start the manufacturing unit. - The prospective investor will receive a 50 percent ownership of the entire registered business entity which includes pharma marketing, third-party medicine manufacturing, and generic pharmaceutical brand name lines of operations. These three will simple be different domains services under one company. - Our business is extremely valuable due to the owner's long standing relationships in the industry and enormous growth potential in the future. The valuation is based on our own estimate. - The business is registered in Raigarh, Maharashtra. However, we run operations from Navi Mumbai, Maharashtra. - Our business is entirely debt-free with no outstanding business loans, overdue, or defaults. - The company has two directors. One of them has a 75 percent ownership of the business. The other owns the remaining 25 percent of the business. There are no outside investors or shareholders.
6.2   Navi Mumbai
Run Rate Sales
USD 600 thousand
EBITDA Margin
25 %
Financial Investment
USD 9 Mn for 50%
Contact Business

Frequently
Asked
Questions

  • How many generic pharmaceutical business investment opportunities are listed on SMERGERS?
    There are 45 active and verified generic pharmaceutical business investment opportunities listed on SMERGERS as of 19 April 2024.
  • What level of due diligence does SMERGERS conduct on the businesses/member?

    SMERGERS scrutinizes all profiles and only features a select group of businesses, investors, advisors that meet a basic requirement. When required, certain members may have submitted some form of proof …read more

  • How active are the business profiles listed on SMERGERS?

    We regularly filter out businesses which are inactive or have already closed a transaction. Typically, if the business is actively looking to sell/raise capital, the status is shown in green.

  • How can I be sure about privacy and confidentiality?

    We understand the level of confidentiality required in strategic transactions and we strive to provide a safe and secure experience for our members. Please review our privacy policy. We …read more

  • How can I contact a business listed on SMERGERS?

    You need to be logged in before you connect with a business. Click here to register and message the business If you are already logged in, please use the contact …read more

  • Should you buy an existing business or start a business from scratch?

    Buying an existing business is generally an easier way to start a business with an immediate head start. It saves valuable time and administrative efforts, considering starting from scratch is …read more

  • How successful has SMERGERS been in helping its users successfully close a deal?

    SMERGERS is a discovery and matchmaking platform with a global reach. It helps in connecting Businesses, Investors, Acquirers, Lenders, M&A Advisors and Boutique Investment Banks across locations, industries and transactions. …read more

  • Show more